# Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

> **NCT01451268** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Johann Wolfgang Goethe University Hospital** · enrollment: 62 (estimated)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Panobinostat
- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT01451268
- **Lead sponsor:** Johann Wolfgang Goethe University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2018-04
- **Final completion:** 2018-04
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2018-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01451268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01451268, "Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01451268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*